AstraZeneca Annual Report and Form 20-F Information 2011

Delivering our strategyOur strategy is to be a focused,integrated, innovation-driven,global, prescription-basedbiopharmaceutical businessWe need the following resources, skills and capabilitiesto deliver our strategy:> An R&D function with world class productivity. See page 30> Cost effective sales and marketing activities focused on ourcustomers’ and patients’ needs. See page 36> A reliable supply and manufacturing operation that ensures ourmedicines are where they need to be when they are needed.See page 38> A talented and diverse workforce with the right capabilitiesoperating in a high performance culture. See page 40Business ReviewThese resources need to be underpinned by:> A well-functioning system of IP rights. See page 34> High quality and flexible support services, including high valueinformation technology and systems. See page 39> Employees acting with integrity. See page 40> A commitment to acting responsibly and to the sustainabledevelopment of our business. See page 47And at the heart of what we do is the need to:> Deliver value through innovation. See page 12> Find solutions through collaboration. See page 26> Earn trust through integrity. See page 44Business ReviewThis section includes information that fulfils the requirements of a business review under theCompanies Act 2006. The Strategy and Performance, Corporate Governance, DevelopmentPipeline, Shareholder Information and Corporate Information sections from pages 15, 99, 199,203 and 208, respectively, are incorporated into this section.Details of the more significant risks to AstraZeneca are set out in the Principal risks anduncertainties section from page 130.Many of our products are subject to litigation. Information about material legal proceedingscan be found in Note 25 to the Financial Statements from page 184.References to prevalence of disease have been derived from a variety of sources and arenot intended to be indicative of the current market or any potential market for AstraZeneca’spharmaceutical products since, among other things, there may be no correlation between theprevalence of a disease and the number of individuals who are treated for such a disease.AstraZeneca Annual Report and Form 20-F Information 2011Delivering our strategy 29